A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: Blood-First Assay Screening Trial)
This is a phase 2/3, global, multicenter, open-label, multi-cohort study designed to evaluate
the safety and efficacy of targeted therapies or immunotherapy as single agents or in
combination in participants with unresectable, advanced or metastatic NSCLC determined to
harbor oncogenic somatic mutations or positive by tumor mutational burden (TMB) assay as
identified by two blood-based next-generation sequencing (NGS) circulating tumor DNA (ctDNA)
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.